Bio

Jin Hwan Chung is a Partner in the Corporate Practice Group and specializes in the areas of healthcare/life sciences, anti-trust and general corporate law, including mergers and acquisitions. He provides legal representation and counsel to numerous leading pharmaceutical and medical devices companies including Archigen Biotech, AstraZeneca, BMS, Bayer, Berna Biotech (Crucell), Daiichi-Sankyo, Eisai, Johnson & Johnson, Janssen, Merck & Co., Mundipharma, Novartis, Novo Nordisk, Takeda, UCB, Boston Scientific, GE Healthcare, Johnson & Johnson Medical and Intuitive Surgical in connection with various transactions and compliance issues. He is one of the highly regarded experts in the area of healthcare compliance issues and a popular lecturer on this matter. As part of his corporate practice, he has also been involved in numerous mergers and acquisitions deals and has advised domestic and foreign clients on anti-trust issues such as the Korea Fair Trade Commission’s investigation into the pharmaceutical industry since 2006. Mr. Chung currently serves as the co-head of the Healthcare/Life Sciences Team of Lee & Ko.